Investor Relations

  • Home
  • Investor Relations
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
Sign up for our News Releases
Head Office
Suite 915 – 700 West Pender Street
Vancouver, BC, Canada • V6C 1G8
© Algernon Pharmaceuticals - All Rights Reserved

Hit enter to search or ESC to close